| Market Cap | 368.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.22M |
| Shares Out | 54.09M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 325,083 |
| Open | 6.86 |
| Previous Close | 6.94 |
| Day's Range | 6.67 - 7.00 |
| 52-Week Range | 2.32 - 10.13 |
| Beta | 2.47 |
| Analysts | Buy |
| Price Target | 7.13 (+4.55%) |
| Earnings Date | Jul 29, 2025 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond ... [Read more]
Financial Performance
In 2024, Fulcrum Therapeutics's revenue was $80.00 million, an increase of 2752.05% compared to the previous year's $2.81 million. Losses were -$9.73 million, -90.01% less than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for FULC stock is "Buy." The 12-month stock price target is $7.13, which is an increase of 4.55% from the latest price.
News
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious ...
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ―
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve th...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of...
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impro...
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impro...
Fulcrum Therapeutics to Participate in Upcoming May Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impro...
Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics to Participate in Upcoming December Conferences
CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Finan...
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impro...
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmace...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therape...
Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therape...
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...